{"id":38405,"date":"2022-12-29T16:39:00","date_gmt":"2022-12-29T15:39:00","guid":{"rendered":"https:\/\/www.etap-lab.com\/?post_type=ressource&#038;p=38405"},"modified":"2026-10-13T17:16:11","modified_gmt":"2026-10-13T15:16:11","slug":"a-novel-vwf-associated-thrombolytic-agent","status":"publish","type":"ressource","link":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/","title":{"rendered":"A novel VWF-associated thrombolytic agent"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Discover this publication on <strong>A novel VWF-associated thrombolytic agent<\/strong>, by Frank W. G. Leebeek, in which in vivo studies were performed by STROK@LLIANCE team on our <a href=\"https:\/\/www.etap-lab.com\/en\/cro-services\/neurovascular-stroke\/in-vivo-models\/#subcat-184\" data-type=\"modele\" data-id=\"3520\">MCA occlusion by FECl3 application in vivo model<\/a>. Published in <strong>Blood (2022) 140 (26): 2770\u20132771.<\/strong> December 29, 2022.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Read the full article<\/strong>: DOI: <a href=\"https:\/\/doi.org\/10.1182\/blood.2022018024\">https:\/\/doi.org\/10.1182\/blood.2022018024<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><em>Connected content: <\/em><\/strong><a href=\"https:\/\/www.etap-lab.com\/en\/ressource\/vwf-targeted-thrombolysis-in-experimental-ischemic-stroke-models\/\" data-type=\"ressource\" data-id=\"38401\">VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-light-color\"><em><strong>Keywords:<\/strong><\/em> ischemic stroke, microlyse, thrombolytic agent, fibrin-rich thrombi, platelet-rich thrombi, cerebral reperfusion.<\/mark><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-primary\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.etap-lab.com\/en\/contact\/\">CONTACT AN EXPERT NOW<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Authors<\/strong>: Frank W. G. Leebeek<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Affiliated<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>1. Erasmus MC, University Medical Center Rotterdam<\/li>\n<\/ul>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-light-color\">ABSTRACT:<\/mark><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-m-font-size\">F<strong>irst results on Microlyse, a novel agent<\/strong> in acute ischemic stroke<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In this issue of <em>Blood<\/em>, van Moorsel et\u00a0al report <strong>the first results on Microlyse, a novel agent with treatment potential that uses a new target to lyse pathologic thrombi in acute ischemic stroke<\/strong>.<a href=\"javascript:;\"><sup>1<\/sup><\/a> In a brief report, they present their mouse studies of experimentally induced stroke treated with either Microlyse, recombinant human tissue-plasminogen activator (rtPA), or vehicle. They show that Microlyse degraded thrombin-induced fibrin-rich thrombi in the middle cerebral artery (MCA), with results comparable to those obtained by rtPA infusion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-m-font-size\"><strong>Microlyse<\/strong>, von Willebrand factor (VWF) and plasminogen activation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Recombinant human tissue plasminogen activator (rh-tPA) is an important thrombolytic agent for treatment of acute ischemic stroke. It requires fibrin binding for plasminogen activation. In contrast, Microlyse, a novel thrombolytic agent, requires von Willebrand factor (VWF) binding for plasminogen activation.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Discover this publication on A novel VWF-associated thrombolytic agent, by Frank W. G. Leebeek, in which in vivo studies were performed by STROK@LLIANCE team on our MCA occlusion by FECl3 application in vivo model. Published in Blood (2022) 140 (26): 2770&ndash;2771. December 29, 2022. Read the full article: DOI: https:\/\/doi.org\/10.1182\/blood.2022018024 Connected content: VWF-targeted thrombolysis to [&hellip;]<\/p>\n","protected":false},"featured_media":38151,"template":"","meta":{"_acf_changed":false},"categorie-de-ressource":[235],"marque-de-ressource":[242],"class_list":["post-38405","ressource","type-ressource","status-publish","has-post-thumbnail","hentry","categorie-de-ressource-publications","marque-de-ressource-strokalliance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A novel VWF-associated thrombolytic agent - ETAP-LAB<\/title>\n<meta name=\"description\" content=\"Report on the first in vivo results obtained using our model of MCA occlusion induced by FECl3, aimed at evaluating the efficacy of Microlyse. A promising thrombolytic agent developed by TargED that requires von Willebrand factor (VWF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A novel VWF-associated thrombolytic agent - ETAP-LAB\" \/>\n<meta property=\"og:description\" content=\"Report on the first in vivo results obtained using our model of MCA occlusion induced by FECl3, aimed at evaluating the efficacy of Microlyse. A promising thrombolytic agent developed by TargED that requires von Willebrand factor (VWF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/\" \/>\n<meta property=\"og:site_name\" content=\"ETAP-LAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-13T15:16:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Publication-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2151\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/\",\"name\":\"A novel VWF-associated thrombolytic agent - ETAP-LAB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ETAP-Ressources-Publication-1.jpg\",\"datePublished\":\"2022-12-29T15:39:00+00:00\",\"dateModified\":\"2026-10-13T15:16:11+00:00\",\"description\":\"Report on the first in vivo results obtained using our model of MCA occlusion induced by FECl3, aimed at evaluating the efficacy of Microlyse. A promising thrombolytic agent developed by TargED that requires von Willebrand factor (VWF).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ETAP-Ressources-Publication-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ETAP-Ressources-Publication-1.jpg\",\"width\":2151,\"height\":1200,\"caption\":\"Illustration for our scientific ressources and Publication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/a-novel-vwf-associated-thrombolytic-agent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ressources\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressources\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Publications\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/categorie-de-ressource\\\/publications\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"A novel VWF-associated thrombolytic agent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"name\":\"Etap Lab\",\"description\":\"CRO Services\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\",\"name\":\"Etap Lab\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"width\":550,\"height\":550,\"caption\":\"Etap Lab\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/etap-lab\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A novel VWF-associated thrombolytic agent - ETAP-LAB","description":"Report on the first in vivo results obtained using our model of MCA occlusion induced by FECl3, aimed at evaluating the efficacy of Microlyse. A promising thrombolytic agent developed by TargED that requires von Willebrand factor (VWF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/","og_locale":"en_US","og_type":"article","og_title":"A novel VWF-associated thrombolytic agent - ETAP-LAB","og_description":"Report on the first in vivo results obtained using our model of MCA occlusion induced by FECl3, aimed at evaluating the efficacy of Microlyse. A promising thrombolytic agent developed by TargED that requires von Willebrand factor (VWF).","og_url":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/","og_site_name":"ETAP-LAB","article_modified_time":"2026-10-13T15:16:11+00:00","og_image":[{"width":2151,"height":1200,"url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Publication-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/","url":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/","name":"A novel VWF-associated thrombolytic agent - ETAP-LAB","isPartOf":{"@id":"https:\/\/www.etap-lab.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/#primaryimage"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Publication-1.jpg","datePublished":"2022-12-29T15:39:00+00:00","dateModified":"2026-10-13T15:16:11+00:00","description":"Report on the first in vivo results obtained using our model of MCA occlusion induced by FECl3, aimed at evaluating the efficacy of Microlyse. A promising thrombolytic agent developed by TargED that requires von Willebrand factor (VWF).","breadcrumb":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/#primaryimage","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Publication-1.jpg","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Publication-1.jpg","width":2151,"height":1200,"caption":"Illustration for our scientific ressources and Publication"},{"@type":"BreadcrumbList","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/a-novel-vwf-associated-thrombolytic-agent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.etap-lab.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ressources","item":"https:\/\/www.etap-lab.com\/en\/ressources\/"},{"@type":"ListItem","position":3,"name":"Publications","item":"https:\/\/www.etap-lab.com\/en\/categorie-de-ressource\/publications\/"},{"@type":"ListItem","position":4,"name":"A novel VWF-associated thrombolytic agent"}]},{"@type":"WebSite","@id":"https:\/\/www.etap-lab.com\/en\/#website","url":"https:\/\/www.etap-lab.com\/en\/","name":"Etap Lab","description":"CRO Services","publisher":{"@id":"https:\/\/www.etap-lab.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.etap-lab.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.etap-lab.com\/en\/#organization","name":"Etap Lab","url":"https:\/\/www.etap-lab.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","width":550,"height":550,"caption":"Etap Lab"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/etap-lab\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/ressource\/38405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/ressource"}],"about":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/types\/ressource"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/media\/38151"}],"wp:attachment":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/media?parent=38405"}],"wp:term":[{"taxonomy":"categorie-de-ressource","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/categorie-de-ressource?post=38405"},{"taxonomy":"marque-de-ressource","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/marque-de-ressource?post=38405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}